

## Friday, 13 October 2017

### 08.45 – 09.00 **Opening and objectives**

C. Chapple, Sheffield (GB)  
F. Cruz, Porto (PT)  
R. Djinic, Belgrade (RS)

### 09.00 – 09.30 **State-of-the-art lecture:**

#### **Can OAB be a consequence of an unrecognised urinary infection?**

Chair: C. Chapple, Sheffield (GB)  
For: A. Tubaro, Rome (IT)  
Against: F. Van Der Aa, Leuven (BE)

### 09.30 – 11.00 **Why do clinical trials not correlate with real life clinical practice?**

Chair: C. Chapple, Sheffield (GB)

#### 09.30 – 09.35 **Setting the scene**

C. Chapple, Sheffield (GB)

#### 09.35 – 09.50 **What are the options for OAB patients with partial response to antimuscarinics?**

F. Van Der Aa, Leuven (BE)

#### 09.50 – 10.05 **Are beta 3 agonists ready to be first line option?**

P. Van Kerrebroeck, Maastricht (NL)

#### 10.05 – 10.20 **OAB refractory to oral medication: Botulinum toxin or sacral neuromodulation?**

S. Arlandis, Valencia (ES)

#### 10.20 – 10.35 **OAB treatment in elderly patients**

M. Kirby, Baldock (GB)

#### 10.35 – 10.50 **Interactive clinical case discussion**

All faculty

#### 10.50 – 11.00 **Take home message**

C. Chapple, Sheffield (GB)

### 11.00 – 11.30 **Coffee break**

### 11.30 – 12.00 **Why is low persistence on treatment a problem for OAB patients?**

Chair: F. Cruz, Porto (PT)  
Discussant: A. Wagg, Alberta (CA)

### 12.00 – 13.00 **The Underactive Bladder**

Chair: P. Van Kerrebroeck, Maastricht (NL)

#### 12.00 - 12.20 **Consensus report on definition**

P. Van Kerrebroeck, Maastricht (NL)

#### 12.20 - 12.40 **Therapeutic options**

C. Chapple, Sheffield (GB)

#### 12.40 - 13.00 **Case discussion and take home messages**

G. Van Koevinge, Maastricht (NL)

### 13.00 – 14.00 **Lunch**

**14.00 – 14.30 State-of-the-art lecture: Nocturia affects both men and women!**  
Case studies – a male patient voiding 4 times a day with nocturia x5 and nocturnal polyuria)  
Chair: K-D. Sievert, Salzburg (AT)  
Discussant: M. Drake, Bristol (GB)

**14.30 – 15.30 Female stress urinary incontinence**  
Chair: F. Cruz, Porto (PT)

**14.30 – 14.35 Setting the scene**  
F. Cruz, Porto (PT)

**14.35 – 14.50 Doctor, if I have the operation, will I be cured forever?**  
Tufan Tarcan, Istanbul (TR)

**14.50 – 15.05 Doctor, I had the surgery but I am still leaking**  
S. Arlandis, Valencia (ES)

**15.05 – 15.20 Should POP and SIU be corrected at the same time?**  
E. Costantini, Perugia (IT)

**15.20 – 15.30 Discussion and take home messages**  
F. Cruz, Porto (PT)

**15.30 – 16.00 Coffee break**

**16.00 – 16.30 State-of-the-art lecture: Quality of Life and its assessment in female urology**  
Chair: M. Drake, Bristol (GB)  
L. Cardozo, London (UK)

**Parallel session EUGA**

**16.30 – 17.30 POP and the use of mesh**  
Chair: L. Cardozo, London (GB)

**16.30 – 16.35 Setting the scene**  
L. Cardozo, London (GB)

**16.35 – 16.45 Pelvic organ prolapse in young women: Which strategy?**  
M. Meschia, Milan (IT)

**16.45 – 16.55 Ageing of the pelvic floor**  
H. Koelbl, Vienna (AT)

**16.55 – 17.05 POP surgery. Native tissue repair: Back to the future**  
S. Salvatore, Milan (IT)

**17.05 – 17.15 POP surgery: When and why I choose laparoscopic or vaginal approach**  
S. Athanasiou, Athens (GR)

**17.15 – 17.30 General discussion and take home message**  
L. Cardozo, London (GB)

**Parallel Session ESGURS**

**16.30 – 17.30 Peyronie's disease**  
Chair: R. Djjinovic, Belgrade (RS)

**16.30 – 16.35 Setting the scene**  
R. Djjinovic, Belgrade (RS)

- 16.35 – 16.50 **Corporoplasty**  
N. Tomada, Porto (PT)
- 16.50 – 17.05 **Doctor, I don't want my penis shortened!**  
S. Sansalone, Rome (IT)
- 17.05 – 17.20 **When is a penile prosthesis is indicated?**  
J. Romero-Otero, Madrid (ES)
- 17.20– 17.30 **Discussion and take home messages**  
R. Djinovic, Belgrade (RS)

**17.30 – 18.00 Boston Scientific Industry Session**

## **Saturday 14 October 2017**

- 08.00 – 08.30 State-of-the-art lecture: Male incontinence after radical prostatectomy. What should I do?**  
Chair: C. Chapple, Sheffield (GB)  
Speaker: J. Heesakkers, Nijmegen (NL)
- 08.30 – 10.00 NDO and incontinence**  
Chair: T. Kessler, Zurich (CH)
- 08.30 – 08.35 Setting the scene**  
T. Kessler, Zurich (CH)
- 08.35 – 08.50 Can I control incontinence with oral medication in MS patients?**  
J. Panicker, London (GB)
- 08.50 – 09.05 When is the moment to introduce botulinum toxin in MS patients?**  
G. Del Popolo, Florence (IT)
- 09.05 – 09.20 How do I follow-up a patient with NDO and spinal cord injury?**  
R. Hamid, London (GB)
- 09.20 – 09.35 When do I stop botulinum toxin and offer bladder augmentation?**  
T. Tarcan, Istanbul (TR)
- 09.35 – 09.55 Interactive clinical case discussion**  
U. Mehnert, Zurich (CH)
- 09.55 – 10.00 Take home message**  
T. Kessler, Zurich (CH)
- 10.00 – 11.00 Dementia and incontinence**  
Chair: J. Heesakkers, Nijmegen (NL)
- 10.00 – 10.05 Setting the scene**  
J. Heesakkers, Nijmegen (NL)
- 10.05 – 10.20 Management of urinary incontinence in a patient with Alzheimer's disease**  
A. Wagg, Alberta (CA)
- 10.20 – 10.35 Antimuscarinic drugs and brain damage: What is the risk?**  
R. Bosch, Utrecht (NL)
- 10.35 – 10.55 Interactive clinical case discussion**  
J. Heesakkers, Nijmegen (NL)
- 10.55 – 11.00 Take home message**  
J. Heesakkers, Nijmegen (NL)

**Parallel session ESGURS**

**08.30 - 11.00 Urethroplasty (semi live surgery)**

Chair: R. Djinovic, Belgrade (RS)

**08.30 – 09.00 To transect the urethra or not?**

C. Chapple, Sheffield (GB)

**09.00 – 09.30 Augmentation or Anastomosis in the borderline case**

R. Dahlem, Hamburg (DE)

**09.30 – 10.00 Female urethroplasty**

C. Chapple, Sheffield (GB)

**10.00 – 10.30 Should we ever use penile skin and when?**

N. Lumen, Ghent (BE)

**10.30 – 11.00 Managing the hypospadiac ‘cripple’**

R. Inman, Sheffield (GB)

**11.00 – 11.30 Coffee Break**

**11.30 – 11.50 State-of-the-art lecture: My patient has a urinary fistula – what should I do?**

**State of the Art**

Chair: F. Cruz, Porto (PT)

Discussant: G. Kasyan, Moscow (RU)

**11.50 – 13.15 My BPH patient needs treatment**

Chair: D. Castro Diaz, Tenerife (ES)

**11.50 – 11.55 Setting the scene**

D. Castro Diaz, Tenerife (ES)

**11.55 - 12.10 One drug, two drugs, three drugs? What the EAU guideline tell us**

M. Oelke, Hanover (DE)

**12.10 - 12.25 Antimuscarinics or beta 3 agonists for males with persistent storage LUTS?**

E. Finazzi Agrò, Rome (IT)

**12.25 – 12.45 Debate: My BPH patient needs surgery**

**I prefer LIFT**

K-D. Sievert, Salzburg (AT)

**TURP is still the gold standard**

M. Oelke, Hanover (DE)

**12.45 - 13.15 Interactive clinical case discussion and take home messages**

D. Castro Diaz, Tenerife (ES)

**13.15 – 14.15 Astellas Industry Session**

**14.15 - 14.45 State-of-the-art lecture: Challenging cases**

Chair: C. Chapple, Sheffield (GB)

Discussant: P. Abrams, Bristol (GB)

- 14.45 – 16.00 Painful Bladder Syndrome (Interstitial cystitis)**  
Chair: R. Peeker, Gothenburg (SE)
- 14.45 – 14.50 Setting the scene**  
R. Peeker, Gothenburg (SE)
- 14.50 – 15.05 Are we talking about a local or a systemic disease?**  
J. Sairanen, Helsinki (FI)
- 15.05 - 15.20 Do mucosal barrier protectors work?**  
M. Lazzeri, Florence (IT)
- 15.20 - 15.35 Is botulinum toxin A the future magic bullet for the management of BPS/IC?**  
F. Cruz, Porto (PT)
- 15.35 – 15.55 Interactive clinical case discussion**  
D. Engeler, St. Gallen (CH)
- 15.55 – 16.00 Take home message**  
R. Peeker, Gothenburg (SE)
- 16.00 – 16.15 Closure**  
C. Chapple, Sheffield (GB)  
F. Cruz, Porto (PT)  
R. Djinovic, Belgrade (RS)